Ovary And Uterus Related Adverse Events Associated With Statin Use: An Analysis Of The FDA Adverse Event Reporting System

The study analyzed data from the FDA Adverse Event Reporting System to investigate the association between statin use and ovary and uterus related adverse events (AEs). It found that statins may be linked to a range of reproductive organ conditions, including various types of neoplasms, uterine disorders, menstrual and sexual function disorders, with variabilities across different statins. Simvastatin, in particular, showed a strong signal for androgenetic alopecia. The study, which performed 15,320 disproportionality analyses, concluded that these potential risks should be closely monitored, although it also recognized limitations such as missing data and the inability to establish causation. Further epidemiologic studies are needed to confirm these findings. The number of people affected by these AEs was not specified in the summary provided.